Form 4: Alnylam Pharmaceuticals CFO Jeffrey Poulton Reports Stock Transactions

Jeffrey Poulton, EVP and CFO of Alnylam Pharmaceuticals, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Summary

• Jeffrey V. Poulton, the EVP and Chief Financial Officer of Alnylam Pharmaceuticals, reported transactions involving the company's common stock.
• On February 27, 2024, Poulton acquired 1,908 shares of common stock through the vesting of restricted stock units.
• Simultaneously, 1,908 shares were sold to cover tax withholding obligations at a price of $0.0.
• From February 28, 2024, Poulton sold a total of 574 shares of common stock in multiple transactions at weighted average prices ranging from $154.54 to $158.09.
• Following these transactions, Poulton directly owns 19,478 shares and indirectly owns 57 shares through a managed account.
• The reported transactions also reflect shares acquired through the issuer's 401(k) plan.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are routine and related to executive compensation and tax obligations. There's no indication of unusual activity or concern.

Positives

• The vesting of restricted stock units indicates that performance milestones were likely met.
• The executive maintains a significant direct ownership stake in the company, aligning his interests with shareholders.

Negatives

• The sale of shares, even for tax obligations, could be perceived negatively by some investors if not properly understood.

Risks

• Executive stock sales, even for tax purposes, can sometimes create short-term price volatility.
• Changes in executive compensation structures or tax laws could impact future transactions.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies, often tied to compensation packages and tax planning strategies. Investors typically monitor these transactions for insights into management's confidence in the company's future prospects.

Comparison to Industry Standards

• Executive compensation packages often include restricted stock units that vest over time, aligning executive interests with long-term shareholder value.
• Sales to cover tax obligations are a standard practice among executives receiving equity compensation.
• Companies like Moderna, BioNTech, and Ionis Pharmaceuticals also have executives who regularly report stock transactions via Form 4 filings.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders.
• Shareholders may be interested in monitoring executive stock transactions as part of their overall assessment of the company.

Key Dates